Short answer
Revvity (RVTY) filed its Q4 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Oct 4, 2026. Quarterly revenue was $729M (up 4.3% year over year) with net income of $62M.
Q4 2026 key financials · XBRL
- Revenue
- $729M
- +4.3% YoY · −0.1% QoQ
- Net income
- $62M
- +33.5% YoY · +20.2% QoQ
- Operating margin
- 13.1%
- EPS (diluted)
- $0.56
- +40.0% YoY · +21.7% QoQ
Source: XBRL data from the Revvity (RVTY) Q4 2026 10-Q on SEC EDGAR. USD.
Revvity Q4 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $728.9M, up 4% YoY from $698.9M
- Life Sciences best performer: revenue $379.6M, up 11%; Diagnostics worst: $349.3M, down 2%
- Gross margin 57.4% vs 53.6%; operating margin 13.1% vs 11.7% YoY
- Cash $592.8M; operating cash flow $484.5M, up from $407.0M
- $571.2M debt repayment; near-term outlook supported by sufficient internal cash for next 12 months
Risk Factors
- Newly highlighted AI risk: flawed algorithms, biased datasets or evolving regulation could create liability, compliance costs and reputational damage
- Most material regulatory update: U.S. funding and regulatory changes are making customers more cautious on instrumentation and consumables
- Near-term market risk: tariff escalation and retaliation may materially hurt results despite manufacturing, supplier and pricing mitigation
- Financial risk: substantial debt includes variable-rate and foreign-currency obligations, increasing interest and currency exposure
- Compliance risk: FDA or foreign regulatory failures could trigger recalls, halted distribution, fines or criminal prosecution
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Revvity quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.